With health care reform expected to be a critical debate in the new presidential administration of Barack Obama, the Biotechnology Industry Organization has unveiled key principles in support of the availability of health care to all US citizens, echoing an earlier move by the Pharmaceutical Research and Manufacturers of America (PhRMA; Marketletter January 19). According to the BIO, any realistic reform proposal must incorporate three principles:
- the public policy goal should be universal access to affordable, high-quality health care for all;
- innovation in health care, including health care solutions such as new therapies and diagnostics, has always been and will continue to be central to realizing health and economic goals; and
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze